Description | Parameter | Log Odds Ratio (95% Interval Estimate) | |
---|---|---|---|
 |  | BPSA | PSA |
Beta blocker | β | -0.21 (-0.37, -0.05) | -0.31 (-0.46, -0.15) |
Demographics | Â | Â | Â |
   Female Sex | γ 1 | 0.17 (0.06, 0.29) | 0.12 (-0.01, 0.25) |
   Age |  |  |  |
< 65 (reference) | . | 0.00 | 0.00 |
65 - 74 | γ 2 | -0.19 (-0.32, -0.04) | -0.09 (-0.3, 0.12) |
75 - 84 | γ 3 | -0.40 (-0.56, -0.24) | -0.21 (-0.41, 0.00) |
> 85 | γ 4 | -0.71 (-0.94, -0.46) | -0.37 (-0.59, -0.14) |
Comorbid conditions | Â | Â | Â |
   Cerebrovascular dis. | γ 5 | -0.11 (-0.67, 0.44) | 0.25 (-0.46, 0.96) |
   COPD | γ 6 | -0.32 (-0.60, -0.06) | -0.89 (-1.30, -0.49) |
   Hyponatremia | γ 7 | -0.02 (-0.26, 0.21) | 0.03 (-0.33, 0.39) |
   Metastatic disorder | γ 8 | -1.42 (-2.33, -0.56) | -0.40 (-1.37, 0.57) |
   Renal disease | γ 9 | -0.17 (-0.32, 0.01) | 0.38 (0.15, 0.62) |
   Ventricular arrhythmia | γ 10 | -0.12 (-0.63, 0.44) | 0.12 (-0.62, 0.86) |
   Liver disease | γ 11 | -0.52 (-1.03, -0.08) | -1.11 (-2.04, -0.19) |
   Malignancy | γ 12 | -0.78 (-1.19, -0.34) | -0.06 (-0.57, 0.45) |
   Shock | γ 13 | -0.06 (-0.56, 0.39) | -0.12 (-0.83, 0.58) |
Hospitalization | Â | Â | Â |
   Transferred | γ 14 | -0.41 (-0.58, -0.25) | -0.01 (-0.22, 0.20) |
   Stay (10 day intvs.) | γ 15 | -0.13 (-0.18, -0.09) | -0.05 (-0.11, 0.01) |
Heart failure medications | Â | Â | Â |
   Digoxin | γ 16 | -0.02 (-0.11, 0.07) | 0.00 (-0.14, 0.13) |
   Diuretic | γ 17 | 0.28 (0.09, 0.48) | 0.72 (0.54, 0.90) |
   CCB | γ 18 | 0.22 (0.08, 0.35) | 0.27 (0.10, 0.44) |
   ACE inhibitor | γ 19 | 0.29 (0.11, 0.45) | 0.61 (0.47, 0.76) |
   ARB | γ 20 | 0.18 (-0.06, 0.46) | 0.53 (0.19, 0.87) |
   Statin | γ 21 | 0.91 (0.65, 1.24) | 0.94 (0.76, 1.12) |